Bio Roundup: Biotech IPOs, Migraine Progress, Takeda Woos Shire & More
Xconomy
MARCH 30, 2018
And the consultancy’s report, finished with one week left. The strength of the IPO market is notable because the first quarter is typically the slowest time of the year for companies to go public, EY told Xconomy. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
52 
Let's personalize your content